Description of drug: Solution of polyvinylpyrrolidone 15% for injection (Solutio Polyvinylpyrrolidoni 15% pro injectionibus)

SOLUTION OF POLYVINYLPYRROLIDONE 15% FOR INJECTIONS (Solutio Polyvinylpyrrolidoni 15% pro injectionibus).

A clear liquid of yellow color with a weak specific smell of polyvinylpyrrolidone; PH 5, 2-7.0; Relative viscosity from 7, 0 to 15, 0.

Polyvinylpyrrolidone is used not only for the manufacture of plasma-substituting solutions (see Haemodes, Neogemodez), but also as a substitute for synovial fluid. For this, polyvinylpyrrolidone with a molecular weight of 35,000 + 5000 is used, which forms colloidal solutions with water.

A solution of polyvinylpyrrolidone (15%) is similar in physical properties to synovial fluid and is used as an artificial substitute for this fluid in diseases of the joints, accompanied by its absence or shortage in the joint space.

The introduction of the solution into the joint cavity improves the sliding of the joint surfaces, prevents the development of adhesions.

Apply the drug with primary and secondary deforming arthrosis, mainly in cases of joints of limbs with functional deficiency without pronounced phenomena of secondary synovitis.

Enter the solution intra-articularly with all the rules of asepsis 1 2 times a week. The solution is stored in the cavity for 5 to 6 days.

The amount of solution depends on the volume of the joint. In the hip joint, usually 4-6 ml, in the knee 5-10 ml, in the ulnar 2-3 ml, in interphalangeal joints 1, 0-1.5 l.

The course of treatment consists of 4 to 6 injections. After 6 - 12 months, repeat the course.

The drug is well tolerated. There is, however, information that in patients with a pronounced local process, synovitis symptoms and unfavorable shifts in the synovial fluid composition are possible (see above).

Product: in ampoules of 5 ml.

Storage: List B. At a temperature of -20 to +20 'C.